Custom Index Systems LLC Has $724,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY)

Custom Index Systems LLC increased its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 74.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,667 shares of the company’s stock after purchasing an additional 2,425 shares during the period. Custom Index Systems LLC’s holdings in Revvity were worth $724,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in RVTY. Rothschild Investment LLC acquired a new stake in shares of Revvity during the 2nd quarter worth approximately $25,000. EverSource Wealth Advisors LLC increased its stake in Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after purchasing an additional 167 shares in the last quarter. Family Firm Inc. acquired a new position in shares of Revvity during the second quarter valued at about $43,000. Fairfield Financial Advisors LTD bought a new position in shares of Revvity during the 2nd quarter worth about $43,000. Finally, EntryPoint Capital LLC bought a new stake in Revvity in the 1st quarter valued at about $48,000. 86.65% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Revvity news, insider Tajinder S. Vohra sold 2,153 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the sale, the insider now owns 23,960 shares of the company’s stock, valued at $2,925,276.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Tajinder S. Vohra sold 2,153 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $122.09, for a total value of $262,859.77. Following the completion of the transaction, the insider now directly owns 23,960 shares in the company, valued at approximately $2,925,276.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total transaction of $412,510.00. Following the sale, the insider now directly owns 33,400 shares in the company, valued at $3,936,524. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,807 shares of company stock valued at $937,576. Company insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on RVTY shares. JPMorgan Chase & Co. increased their price target on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Bank of America boosted their target price on shares of Revvity from $118.00 to $127.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Wells Fargo & Company initiated coverage on shares of Revvity in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target on the stock. TD Cowen increased their price objective on Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, Citigroup lifted their target price on Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $127.20.

Revvity Stock Performance

Revvity stock traded up $0.19 during trading on Friday, hitting $116.33. The stock had a trading volume of 733,601 shares, compared to its average volume of 641,421. The stock’s 50 day moving average is $121.51 and its two-hundred day moving average is $113.49. Revvity, Inc. has a 1 year low of $79.50 and a 1 year high of $128.15. The stock has a market cap of $14.35 billion, a price-to-earnings ratio of 96.14, a price-to-earnings-growth ratio of 3.27 and a beta of 1.05. The company has a quick ratio of 1.98, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.10. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company had revenue of $691.70 million during the quarter, compared to the consensus estimate of $690.33 million. During the same quarter in the prior year, the company earned $1.21 EPS. The firm’s quarterly revenue was down 2.5% compared to the same quarter last year. As a group, analysts predict that Revvity, Inc. will post 4.75 EPS for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date is Friday, January 17th. Revvity’s payout ratio is currently 23.14%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.